Skip to main content
main-content

11-02-2021 | ASCO GU 2021 | Conference coverage | Video

Single-agent atezolizumab supported for some cisplatin-ineligible mUC patients

Speaker: Matthew Galsky

Matthew Galsky shares exploratory data from the IMvigor130 trial suggesting the benefit of atezolizumab monotherapy in certain cisplatin-ineligible patients with advanced urothelial carcinoma (6:13).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Read transcript

Image Credits